HC Wainwright Has Pessimistic Outlook of BEAM Q3 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share estimates for shares of Beam Therapeutics in a research note issued to investors on Friday, August 7th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($1.25) per share for the quarter, down from their prior forecast of ($1.01). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.37) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q4 2026 earnings at ($1.29) EPS, FY2026 earnings at ($4.64) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.27) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($5.08) EPS, FY2028 earnings at ($3.83) EPS, FY2029 earnings at ($2.71) EPS and FY2030 earnings at ($1.61) EPS.

A number of other analysts have also commented on BEAM. Wall Street Zen lowered Beam Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Sanford C. Bernstein reduced their price objective on shares of Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Tudor Pickering set a $39.00 price objective on shares of Beam Therapeutics in a report on Wednesday, May 13th. Bank of America reaffirmed a “buy” rating and issued a $47.00 target price on shares of Beam Therapeutics in a research report on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Beam Therapeutics in a research note on Friday, July 17th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.00.

Beam Therapeutics Price Performance

BEAM opened at $27.28 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 14.57 and a current ratio of 14.57. The stock has a market capitalization of $2.82 billion, a PE ratio of -31.72 and a beta of 2.23. The stock’s 50 day moving average price is $30.54 and its 200-day moving average price is $28.93. Beam Therapeutics has a 52-week low of $15.60 and a 52-week high of $38.26.

Beam Therapeutics (NASDAQ:BEAM) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.07). The business had revenue of $0.49 million during the quarter, compared to analysts’ expectations of $16.37 million. Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%.The company’s quarterly revenue was down 94.2% compared to the same quarter last year. During the same quarter last year, the business posted ($1.00) EPS.

Hedge Funds Weigh In On Beam Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of BEAM. BlackRock Inc. purchased a new position in shares of Beam Therapeutics in the 2nd quarter worth about $308,796,000. ADAR1 Capital Management LLC purchased a new stake in Beam Therapeutics during the 1st quarter valued at about $34,467,000. ARK Investment Management LLC grew its position in Beam Therapeutics by 12.9% during the 4th quarter. ARK Investment Management LLC now owns 12,467,189 shares of the company’s stock valued at $345,590,000 after purchasing an additional 1,428,355 shares during the last quarter. MWG Caph Ltd bought a new stake in Beam Therapeutics during the 4th quarter valued at about $35,119,000. Finally, State Street Corp increased its stake in Beam Therapeutics by 30.4% during the 4th quarter. State Street Corp now owns 5,228,529 shares of the company’s stock valued at $144,935,000 after purchasing an additional 1,219,871 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Fmr Llc sold 251,488 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $35.26, for a total value of $8,867,466.88. Following the sale, the insider owned 854,583 shares in the company, valued at $30,132,596.58. This represents a 22.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Amy Simon sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $25.74, for a total value of $429,008.58. Following the transaction, the insider directly owned 85,696 shares of the company’s stock, valued at approximately $2,205,815.04. This trade represents a 16.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 301,527 shares of company stock worth $10,468,500. Insiders own 3.80% of the company’s stock.

Key Headlines Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating despite lowering estimates, indicating the firm continues to see long-term value in Beam’s base-editing platform and pipeline.
• Positive Sentiment: J.P. Morgan also maintained its Buy rating on Beam, providing some support for the bullish long-term investment thesis. J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics
• Neutral Sentiment: HC Wainwright’s updated forecasts call for losses of $4.64 per share in fiscal 2026, $5.08 in fiscal 2027, $3.83 in fiscal 2028, $2.71 in fiscal 2029 and $1.61 in fiscal 2030. The estimates still imply improving results after 2027, but profitability remains distant.
• Negative Sentiment: The firm cut its fiscal 2026 loss forecast from $3.95 to $4.64 per share and its fiscal 2027 loss forecast from $3.86 to $5.08 per share. It also reduced estimates for each quarter from the third quarter of 2026 through the fourth quarter of 2027.
• Negative Sentiment: Longer-term revisions were also unfavorable: the projected fiscal 2028 loss widened from $2.78 to $3.83 per share, fiscal 2029 from $2.09 to $2.71, and fiscal 2030 from $1.46 to $1.61. These cuts reinforce concerns about higher development costs, continued cash burn and delayed earnings improvement.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.